NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints

Dow Jones

Nov 20, 2024

By Colin Kellaher

NewAmsterdam Pharma on Wednesday said a late-stage study of its proposed cholesterol drug combination met its key goals, paving the way for the biopharmaceutical company to seek regulatory approval.

NewAmsterdam said the Phase 3 study of a fixed-dose combination of obicetrapib and ezetimibe met all co-primary endpoints in reduction in low-density lipoprotein cholesterol in adults with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease or related risk factors.

The Netherlands-based company said the study results will support global regulatory filings for combination in such adults whose LDL-C isn't adequately controlled despite being on maximally tolerated lipid-lowering therapy.

Trading in shares of NewAmsterdam, which closed Tuesday at $23.68, was halted premarket on Wednesday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 20, 2024 07:35 ET (12:35 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2484118805"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484118805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2484118805?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484118805","market":"fut","top_or_hot":-1,"title":"NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  NewAmsterdam Pharma on Wednesday said a late-stage study of its proposed cholesterol drug combination met its key goals, paving the way for the biopharmaceutical company to seek regulatory approval. \n</p>\n<p>\n  NewAmsterdam said the Phase 3 study of a fixed-dose combination of obicetrapib and ezetimibe met all co-primary endpoints in reduction in low-density lipoprotein cholesterol in adults with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease or related risk factors. \n</p>\n<p>\n  The Netherlands-based company said the study results will support global regulatory filings for combination in such adults whose LDL-C isn't adequately controlled despite being on maximally tolerated lipid-lowering therapy. \n</p>\n<p>\n  Trading in shares of NewAmsterdam, which closed Tuesday at $23.68, was halted premarket on Wednesday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 07:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-20 20:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  NewAmsterdam Pharma on Wednesday said a late-stage study of its proposed cholesterol drug combination met its key goals, paving the way for the biopharmaceutical company to seek regulatory approval. \n</p>\n<p>\n  NewAmsterdam said the Phase 3 study of a fixed-dose combination of obicetrapib and ezetimibe met all co-primary endpoints in reduction in low-density lipoprotein cholesterol in adults with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease or related risk factors. \n</p>\n<p>\n  The Netherlands-based company said the study results will support global regulatory filings for combination in such adults whose LDL-C isn't adequately controlled despite being on maximally tolerated lipid-lowering therapy. \n</p>\n<p>\n  Trading in shares of NewAmsterdam, which closed Tuesday at $23.68, was halted premarket on Wednesday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 07:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2484118805","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484118805","pubTimestamp":1732106100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"NewAmsterdam Pharma on Wednesday said a late-stage study of its proposed cholesterol drug combination met its key goals, paving the way for the biopharmaceutical company to seek regulatory approval.The Netherlands-based company said the study results will support global regulatory filings for combination in such adults whose LDL-C isn't adequately controlled despite being on maximally tolerated lipid-lowering therapy.Trading in shares of NewAmsterdam, which closed Tuesday at $23.68, was halted premarket on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NAMS":"NEWAMSTERDAM PHARMA CO NV"},"translate_title":"NewAmsterdam Pharma 3期药物组合研究达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAMS":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  NewAmsterdam Pharma on Wednesday said a late-stage study of its proposed cholesterol drug combination met its key goals, paving the way for the biopharmaceutical company to seek regulatory approval. \n\n\n  NewAmsterdam said the Phase 3 study of a fixed-dose combination of obicetrapib and ezetimibe met all co-primary endpoints in reduction in low-density lipoprotein cholesterol in adults with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease or related risk factors. \n\n\n  The Netherlands-based company said the study results will support global regulatory filings for combination in such adults whose LDL-C isn't adequately controlled despite being on maximally tolerated lipid-lowering therapy. \n\n\n  Trading in shares of NewAmsterdam, which closed Tuesday at $23.68, was halted premarket on Wednesday. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 07:35 ET (12:35 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}